Compare BridgeBio Pharma Inc (BBIO) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while State Street SPDR S&P Homebuilders ETF trades at $110.22. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | XHB | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $121.36 |
52-Week Low | $47.29 | $94.86 |
Enterprise Value | $18.14B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
